November 30, 2022Clarametyx Initiates Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101 Against Community-Acquired Bacterial PneumoniaRead More October 5, 2022Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101Read More April 4, 2022CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-biofilm Technology for Life-threatening Bacterial InfectionsRead More December 20, 2021Clarametyx Biosciences Awarded $3.15 Million Grant From NIH to Advance a Broad-spectrum Vaccine Technology for Bacterial InfectionsRead More November 5, 2021New Publication in Cell Implicates a Rare Form of DNA Driving Antimicrobial Resistance in Bacterial BiofilmsRead More September 1, 2021Clarametyx Biosciences Awarded $2.7 Million in Option Funding From CARB-X to Accelerate Novel Technology for Persistent Bacterial InfectionsRead More May 20, 2021Clarametyx Biosciences Expands Board of Directors with Appointment of Financial Executive Michael LaymanRead More March 15, 2021Clarametyx featured in 2021 Technology Showcase, hosted by Nationwide Children’s Hospital’s Office of Technology CommercializationRead More January 5, 2021David Richards Appointed CEO of Clarametyx BiosciencesRead More
